If you used Roundup weed killer and developed non-Hodgkin lymphoma, here is what Bayer’s massive new settlement would actually put in your pocket: between $6,000 and $165,000, depending on how you were exposed, when you were diagnosed, and how aggressive your cancer is. That is a far cry from the $7.25 billion headline number, and an even further cry from the $289 million a jury once awarded a single plaintiff back in 2018. The gap between the settlement’s total price tag and individual payouts is worth understanding before you make any decisions about opting in or out.
Bayer announced the proposed class-action settlement on February 17, 2026, and a Missouri judge granted preliminary approval on March 4, 2026. The deal is designed to resolve not just the roughly 58,000 active Roundup cancer claims but also future claims from people who may be diagnosed with non-Hodgkin lymphoma over the next 16 years. That 21-year payout window is unusual and controversial. This article breaks down how the nine-tier payment system works, who qualifies, what the quick-pay option gets you, why thousands of attorneys are fighting the deal, and what a pending Supreme Court case could mean for anyone still on the fence.
Table of Contents
- How Much Would You Actually Receive from the $7.25 Billion Roundup Settlement?
- Who Qualifies for the Roundup Cancer Settlement and Who Does Not
- Why Bayer’s $18 Billion Roundup Tab Still Has Not Settled the Problem
- Quick-Pay vs. Full Claim — Which Path Makes More Sense
- The Supreme Court Case That Could Change Everything
- What Bayer’s “No Admission of Liability” Actually Means for You
- What Happens Next and What You Should Do Before June 4
- Conclusion
- Frequently Asked Questions
How Much Would You Actually Receive from the $7.25 Billion Roundup Settlement?
The $7.25 billion figure sounds enormous until you divide it across tens of thousands of current claimants and potentially tens of thousands more future ones over two decades. Bayer has structured the settlement into nine tiers based on three factors: whether your exposure was occupational or residential, your age at diagnosis, and whether your non-Hodgkin lymphoma is classified as fast-growing or slow-growing. Occupational users — farmworkers, landscapers, groundskeepers, anyone who handled Roundup regularly as part of their job — can receive up to $165,000. Residential users, meaning people who sprayed it on their driveways and garden beds a few times a year, max out at $40,000. Consider a concrete example. A 55-year-old landscaper diagnosed with aggressive diffuse large B-cell lymphoma after 20 years of daily Roundup exposure sits near the top of the tier system. That person could receive something approaching $165,000.
A 70-year-old retiree who used Roundup occasionally in the backyard and was diagnosed with a slow-growing follicular lymphoma lands much lower — probably in the range of $10,000 to $25,000. These are not life-changing sums for people dealing with cancer treatment costs, lost income, and diminished quality of life. There is also a quick-pay option designed for claimants who want money faster without navigating the full claims process. Quick-pay amounts range from $6,000 to $14,500. That is not a typo. For context, a single round of chemotherapy can cost $10,000 to $200,000 depending on the drugs and duration. The quick-pay route trades speed for money, and for some people — particularly those who are elderly or facing mounting bills — that tradeoff might make sense. But no one should mistake it for fair compensation.
Who Qualifies for the Roundup Cancer Settlement and Who Does Not
Eligibility comes with specific criteria that will exclude some people who assume they qualify. You must have been exposed to Roundup products before February 17, 2026 — the date the settlement was announced. And you must have been diagnosed with non-Hodgkin lymphoma, either already or within the next 16 years. Other cancers linked in some research to glyphosate exposure, such as certain leukemias, are not covered under this deal. If your diagnosis is something other than non-Hodgkin lymphoma, this settlement does not apply to you. The future-claims provision is one of the most contentious parts of the settlement. It covers people who have not yet been diagnosed but may develop non-Hodgkin lymphoma years from now.
However, if you are diagnosed 17 years from now — in 2043 — you would fall outside the settlement window and would need to pursue claims independently. That is a real limitation. Non-Hodgkin lymphoma can take decades to develop after chemical exposure, and a 16-year window may not capture everyone who was harmed. Attorneys opposing the deal have pointed to this as a fundamental flaw. One critical thing to understand: if you do nothing and the settlement receives final approval, you are automatically included as a class member. That means you give up your right to sue Bayer individually. If you believe your case is strong enough to win more at trial — or if you are philosophically opposed to the settlement terms — you must actively opt out by June 4, 2026. Missing that deadline locks you in.
Why Bayer’s $18 Billion Roundup Tab Still Has Not Settled the Problem
Bayer has now committed roughly $18.25 billion to Roundup litigation — $11 billion in prior settlements covering nearly 100,000 cases, plus this new $7.25 billion proposal. For perspective, Bayer paid $63 billion to acquire Monsanto in 2018, the same year a California jury hit the company with a $289 million verdict in the Dewayne Johnson case. Johnson, a school groundskeeper diagnosed with terminal non-Hodgkin lymphoma, became the public face of Roundup litigation. His verdict was later reduced to $20.5 million on appeal, but it opened the floodgates. The sheer volume of litigation has been staggering. At its peak, Bayer faced more than 125,000 claims.
The company settled the bulk of them in 2020 for $10.9 billion, but new cases kept coming. The current settlement is Bayer’s attempt to draw a line — not just resolving existing claims but capping its exposure to future ones over a 21-year period. The company is essentially buying finality, or trying to. Yet approximately 58,000 active claims remain, and attorneys representing roughly 20,000 of those plaintiffs have formally opposed the settlement. Their argument is straightforward: the per-person payouts are inadequate given the severity of the injuries, and the deal is structured to benefit Bayer more than the people it harmed. Whether the judge agrees will be determined at the fairness hearing scheduled for July 9, 2026.
Quick-Pay vs. Full Claim — Which Path Makes More Sense
The settlement offers two routes, and the choice between them involves real tradeoffs. The full claims process assigns you to one of nine tiers based on your exposure type, cancer severity, and age. It takes longer but can yield substantially more money — up to $165,000 for occupational users with aggressive cancers. The quick-pay option gets you $6,000 to $14,500 faster, with less documentation and fewer hurdles. For someone who is terminally ill and needs money now, quick-pay may be the practical choice. For someone in remission with strong documentation of occupational exposure, the full claims process is almost certainly worth the wait.
The difference between $14,500 and $165,000 is not trivial, and the documentation requirements — medical records, proof of Roundup use, employment history — are things most claimants should be gathering regardless. One important caveat: Bayer will make annual payments into a special fund over 21 years, which means even the full claims process may not result in a single lump-sum payment. The timing of your payout depends on when your claim is processed and where Bayer is in its payment schedule. If you are weighing whether to opt out entirely and pursue individual litigation, consider this: Bayer deposited $500 million within 10 days of preliminary approval for notification and administration costs alone. The company is heavily invested in making this settlement work. Going it alone means betting that you can win more at trial — possible, but increasingly uncertain given the Supreme Court case looming over the entire litigation.
The Supreme Court Case That Could Change Everything
While the settlement works its way through the Missouri court system, the U.S. Supreme Court is preparing to hear arguments in April 2026 on a question that could reshape the entire Roundup litigation landscape. The central issue: does the EPA’s approval of Roundup without a cancer warning preempt state-court lawsuits that claim the product should have carried such a warning? If the Court rules in Bayer’s favor, it could effectively shut down future failure-to-warn claims — the legal theory that most Roundup plaintiffs rely on. A ruling for Bayer would not retroactively undo this settlement, but it would dramatically weaken the bargaining position of anyone who opts out. If you leave the settlement class thinking you will get more at trial, and the Supreme Court then eliminates your primary legal theory, you could end up with nothing.
This is the single biggest risk factor for claimants considering opting out. On the other hand, if the Court rules against Bayer, the current settlement payouts will look even more inadequate, and those who opted out may be vindicated. The timing is not accidental. Bayer proposed this settlement knowing the Supreme Court case was coming. Locking in a $7.25 billion deal before a potentially favorable ruling is a strategic hedge. Claimants need to understand that they are making decisions in a window of legal uncertainty, and the June 4, 2026 opt-out deadline arrives before the Supreme Court is likely to issue its opinion.
What Bayer’s “No Admission of Liability” Actually Means for You
Buried in the settlement terms is a clause that matters more than most people realize: Bayer is not admitting that Roundup causes cancer. The company continues to maintain that glyphosate-based herbicides are safe. This is standard in class-action settlements, but it has practical consequences. It means Bayer can continue selling Roundup without a cancer warning label.
It means the settlement cannot be cited as evidence in future litigation that Bayer knew its product was dangerous. And it means that if you develop non-Hodgkin lymphoma after the settlement window closes, you cannot point to this deal as proof of a causal link. For the people receiving payouts, this may feel like an insult on top of injury. You are being compensated for a cancer that the company paying you insists it did not cause. But the legal system draws a sharp distinction between settling claims and admitting fault, and Bayer’s lawyers have made sure that distinction is ironclad in this agreement.
What Happens Next and What You Should Do Before June 4
The next major milestone is the June 4, 2026 deadline for class members to file objections or opt out. If you do nothing, you are in. After that, the fairness hearing on July 9, 2026 will determine whether the settlement receives final approval.
The judge will consider objections, evaluate the adequacy of the payouts, and decide whether the deal is fair to the class as a whole. If you or someone you know used Roundup and has been diagnosed with non-Hodgkin lymphoma, the most important thing you can do right now is gather documentation: medical records, purchase receipts or employment records showing Roundup use, and any correspondence you have had with attorneys. Whether you stay in the settlement or opt out, that documentation is your foundation. And watch the Supreme Court docket closely — the April 2026 oral arguments may be the single most important factor in determining whether this settlement is a reasonable deal or a lowball offer dressed up as closure.
Conclusion
Bayer’s $7.25 billion Roundup settlement is the latest chapter in one of the most expensive product liability sagas in corporate history. The company has now committed over $18 billion to resolve claims that its flagship herbicide causes cancer — all while insisting it does not. For individual claimants, the math is sobering: occupational users can receive up to $165,000, residential users up to $40,000, and quick-pay recipients as little as $6,000. These are not numbers that make anyone whole after a cancer diagnosis.
The June 4, 2026 opt-out deadline is the most consequential date on the calendar for anyone affected. Staying in the settlement guarantees some compensation but forecloses the possibility of a larger individual verdict. Opting out preserves your right to sue but carries real risk, especially with the Supreme Court poised to potentially narrow the legal theories available to Roundup plaintiffs. There is no universally right answer — only the one that fits your specific diagnosis, financial situation, and tolerance for legal uncertainty. Whatever you decide, do it with full information, not just the headline number.
Frequently Asked Questions
Do I need a lawyer to file a claim in the Roundup settlement?
You are not legally required to have an attorney, but the claims process involves medical documentation, tier classification, and potential disputes over payout amounts. Most claimants benefit from legal representation, and many Roundup attorneys work on contingency, meaning they only get paid if you do.
What if I used Roundup but have not been diagnosed with non-Hodgkin lymphoma yet?
You are still covered under the settlement if you are diagnosed within the next 16 years — through approximately 2042. However, you cannot file a claim until you have an actual diagnosis. If you are diagnosed after the 16-year window closes, you would not be covered by this settlement.
Can I opt out now and rejoin the settlement later if the Supreme Court rules in Bayer’s favor?
No. The opt-out deadline is June 4, 2026, and it is a one-way door. Once you opt out, you cannot rejoin the settlement class. You would need to pursue your claims independently through the court system.
How long will it take to actually receive money from this settlement?
Bayer is making payments into the settlement fund over 21 years. How quickly you receive your payout depends on when your claim is processed and approved. The quick-pay option is designed for faster disbursement, but exact timelines have not been publicly specified for the full claims process.
Does this settlement affect Roundup products currently on store shelves?
No. Bayer is not admitting liability or agreeing to change Roundup’s formulation or labeling. The product remains on the market without a cancer warning, and the EPA continues to classify glyphosate as not likely to be carcinogenic to humans.